St. James' University Hospital

Leeds, West Yorkshire LS97TF

1 studies enrolling now · 7 studies all time

What they study most

Epithelial Ovarian Cancer, Fallopian Tube Cancer, GIST, Glioma, H3 K27M, HER2-Positive Primary Breast Cancer, Heart Failure, Mantle-Cell Lymphoma, Ovarian Cancer, Peritoneal Cancer, Residual Invasive Breast Cancer

Studies at this site

• ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib — Running, not enrolling
• Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) — Completed
• A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) — Completed
• Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) — Completed
• Warfarin and Antiplatelet Therapy in Chronic Heart Failure — Completed